EMA grants additional marketing authorisations for NexGard®, NexGard SPECTRA® and Broadline®

Boehringer Ingelheim has announced the European Medicines Agency has granted further marketing authorisations for NexGard®, NexGard SPECTRA® and Broadline®, maximizing their preventive impact and keeping pets and humans safer. One new authorisation concerns the Ixodes hexagonus tick, prevalent in many EU countries, which infest and feeds on cats, dogs and sometimes humans, and potentially transmits the causes of Lyme disease. A second authorisation is to help prevent thelaziosis, which is spreading to the EU, which leads to conjunctivitis and keratitis, and potentially corneal ulcers, perforation and blindness. The third authorization is for the treatment of intestinal infestations with Ancylostoma ceylanicum hookworm which affects dogs and cats, which can cause chronic intestinal blood loss leading to anaemia. This is the only hookworm that fully develops in humans, causing the same clinical signs as in companion animals.
Jean-Luc Michel, Head of BI’s Companion Animals Business Unit, said: “We are extremely pleased with the approval of these new indications by EMA. They are a testimony to our strong focus on prevention and improving health of animals.”